According to 17 analysts, the average rating for EXAS stock is “Buy.” The 12-month stock price forecast is $94.86, which is an increase of 20.70% from the latest price. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Exact Sciences issued an update on its FY 2023 earnings guidance on Wednesday, June, 28th.
- Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”).
- It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer.
- The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
- The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. The table below shows EXAS’s growth in key financial areas (numbers in millions of US dollars). Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”).
Related Articles EXAS
This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.40 billion-$2.40 billion, compared to the consensus revenue estimate of $2.42 billion. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.
To see all exchange delays and terms of use, please see disclaimer. For more insight on analysts targets of EXAS, see our EXAS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship momentum indicator forex between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Results of three modeling studies demonstrated that non-invasive colorectal cancer screening with Cologuard® is more effective when compared to hypothetical blood-based screening1-3 MADISON, Wis. , Ma…
And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. EXAS’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Morningstar analysts hand-select direct competitors or comparable companies to
provide context on the strength and durability of EXAS’s
competitive advantage. Exact Sciences’ approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program anal… One share of EXAS stock can currently be purchased for approximately $78.59.
Cathie Wood Boosts Coinbase, Tesla Holdings, Cuts Back Exact Sciences
The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual https://bigbostrade.com/ securities. Exact Sciences’ stock was trading at $49.51 at the beginning of 2023. Since then, EXAS shares have increased by 58.7% and is now trading at $78.59. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.
Please see Open to the Public Investing’s Fee Schedule to learn more. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.
How do I buy Exact Sciences (EXAS) stock?
In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Exact Sciences said on Tuesday its next-generation screening test for colon cancer showed 30% lower false positive rate for detecting the disease in a study when compared to trial data on its already …
Exact Sciences’s Q3 earnings are confirmed for Thursday, November 2, 2023. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.
Both companies have outperformed the market over the past year.
Is It Time to Sell EXAS? Shares are down today.
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account.
All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI. High-growth stocks tend to represent the technology, healthcare, and communications sectors.
Style is calculated by combining value and growth scores, which are first individually calculated. MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. You can find your newly purchased EXAS stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. The technique has proven to be very useful for finding positive surprises.